Publications by authors named "Sauer T"

Article Synopsis
  • The European LeukemiaNet (ELN) updated its risk classification for acute myeloid leukemia (AML) patients in 2022 (ELN22) and a study evaluated its effectiveness on 1,570 newly diagnosed patients.
  • Compared to the previous 2017 classification (ELN17), the new ELN22 showed a similar distribution of risk categories but reclassified 22% of patients, mostly into intermediate or adverse groups, resulting in better prognostic accuracy, particularly for overall survival (OS).
  • The study found significant differences in survival rates based on specific gene mutations within the adverse risk group, highlighting the need for tailored treatment approaches based on genetic factors.
View Article and Find Full Text PDF
Article Synopsis
  • * The case of a 33-year-old pregnant woman from East Africa illustrates a misdiagnosis of a mesenteric cyst, initially thought to be an ovarian cyst, which later turned out to be a ruptured hydatid cyst after postpartum complications.
  • * Successful management required prompt recognition and treatment using antiparasitic medication and surgery, highlighting the importance of accurate diagnosis and a multidisciplinary approach for rare conditions.
View Article and Find Full Text PDF
Article Synopsis
  • Venetoclax (VEN) is a medicine that helps treat a type of blood cancer called acute myeloid leukemia (AML) for patients who can't have intensive treatments.
  • In a study comparing patients treated with VEN to those with other treatments, more VEN patients responded well (62% vs. 42%).
  • The study suggests that using VEN helps these patients have longer periods without problems and might lead to better survival rates, making it a good option before a major transplant procedure.
View Article and Find Full Text PDF

Background: Relapsed and refractory acute myeloid leukemia (AML) carries a dismal prognosis. CAR T cells have shown limited efficacy in AML, partially due to dysfunctional autologous T cells and the extended time for generation of patient specific CAR T cells. Allogeneic NK cell therapy is a promising alternative, but strategies to enhance efficacy and persistence may be necessary.

View Article and Find Full Text PDF

Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m with 90 mg/m daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction.

Patients And Methods: Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle.

View Article and Find Full Text PDF

Objective: In this study, we investigated pivotal molecular markers in human high-grade breast ductal carcinoma (DCIS). Expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2) was measured among various subtypes (Luminal (Lum) A, LumB HER2, LumB HER2, HER2-enriched and triple-negative).

Methods: In total, 357 DCIS cases were classified into respective subtypes, according to the 2013 St.

View Article and Find Full Text PDF
Article Synopsis
  • In newly diagnosed acute myeloid leukemia (AML), immediate treatment is typical; however, sometimes treatment may be delayed to evaluate other health issues or risks.
  • A study analyzed the effects of the timing of treatment initiation on outcomes for patients receiving venetoclax-based therapy, comparing two patient groups with average ages of 76 and 72.
  • Results showed no significant difference in overall survival or complications (like severe infections) between those who started treatment within 10 days versus later, suggesting that delaying therapy may be safe for certain patients with proper monitoring.
View Article and Find Full Text PDF
Article Synopsis
  • The study compares the effectiveness of two cancer drugs, letrozole and exemestane, in lowering estrogen levels for postmenopausal women with ER-positive breast cancer.
  • Patients participated in an intra-patient cross-over design, first receiving one drug followed by the other, while serum estrogen and drug levels were measured using a sensitive laboratory method.
  • Results showed that letrozole was more effective at reducing estrogen levels compared to exemestane, with significant decreases observed after treatment with either drug.
View Article and Find Full Text PDF

The remarkable efficacy of Epstein-Barr virus (EBV)-specific T cells for the treatment of posttransplant lymphomas has not been reproduced for EBV-positive (EBV+) malignancies outside the transplant setting. This is because of, in part, the heterogeneous expression and poor immunogenicity of the viral antigens expressed, namely latent membrane proteins 1 and 2, EBV nuclear antigen 1, and BamHI A rightward reading frame 1 (type-2 [T2] latency). However, EBV lytic cycle proteins are also expressed in certain EBV+ malignancies and, because several EBV lytic cycle proteins are abundantly expressed, have oncogenic activity, and likely contribute to malignancy, we sought and identified viral lytic-cycle transcripts in EBV+ Hodgkin lymphoma biopsies.

View Article and Find Full Text PDF

Background: Extracellular vesicles (EVs), including microvesicles, hold promise for the management of bladder urothelial carcinoma (BLCA), particularly because of their utility in identifying therapeutic targets and their diagnostic potential using easily accessible urine samples. Among the transmembrane glycoproteins highly enriched in cancer-derived EVs, tissue factor (TF) and CD147 have been implicated in promoting tumor progression. In this in vitro study, we explored a novel approach to impede cancer cell migration and metastasis by simultaneously targeting these molecules on urothelial cancer-derived EVs.

View Article and Find Full Text PDF
Article Synopsis
  • Graft-versus-host disease (GVHD) can happen to people who receive special T-cells after a stem cell transplant, affecting 10% to 33% of them.
  • A treatment called extracorporeal photopheresis (ECP) seems to help with GVHD while still allowing the T-cells to fight cancer and infections.
  • Research showed that ECP can make these T-cells less likely to cause problems in the body, while still keeping them effective for fighting diseases.
View Article and Find Full Text PDF

Background: As a leading cause of death, worldwide, cardiovascular disease is of great clinical importance. Among cardiovascular diseases, coronary artery disease (CAD) is a key contributor, and it is the attributed cause of death for 10% of all deaths annually. The prevalence of CAD is commensurate with the rise in new medical imaging technologies intended to aid in its diagnosis and treatment.

View Article and Find Full Text PDF

Purpose: We aimed to identify subsets of patients who benefit from emergency LA and to establish a therapeutic algorithm for AML patients with hyperleukocytosis.

Methods: In this single-center retrospective cohort study, a total of 20 consecutive patients underwent LA because of their clinical symptoms. Overall survival (OS) analysis was conducted using the Kaplan-Meier plot method.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) is a hematologic malignancy for which allogeneic hematopoietic cell transplantation (allo-HCT) often remains the only curative therapeutic approach. However, incapability of T cells to recognize and eliminate residual leukemia stem cells might lead to an insufficient graft-versus-leukemia (GVL) effect and relapse. Here, we performed single-cell RNA-sequencing (scRNA-seq) on bone marrow (BM) T lymphocytes and CD34+ cells of 6 patients with AML 100 days after allo-HCT to identify T-cell signatures associated with either imminent relapse (REL) or durable complete remission (CR).

View Article and Find Full Text PDF

Virtual imaging trials enable efficient assessment and optimization of medical image devices and techniques via simulation rather than physical studies. These studies require realistic, detailed ground-truth models or phantoms of the relevant anatomy or physiology. Anatomical structures within computational phantoms are typically based on medical imaging data; however, for small and intricate structures (e.

View Article and Find Full Text PDF

Lung cancer is the leading cause of cancer-related deaths worldwide with lung adenocarcinoma (LUAD) being the most common type. Genomic studies of LUAD have advanced our understanding of its tumor biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD are still insufficiently explored.

View Article and Find Full Text PDF

The efficacy of therapeutic T-cells is limited by a lack of positive signals and excess inhibitory signaling in tumor microenvironments. We previously showed that a constitutively active IL7 receptor (C7R) enhanced the persistence, expansion, and anti-tumor activity of T-cells expressing chimeric antigen receptors (CARs), and C7R-modified GD2.CAR T-cells are currently undergoing clinical trials.

View Article and Find Full Text PDF

Purpose: Despite recent advances in adapting the intensity of treatment for older patients with ALL, current protocols are associated with high rates of early deaths, treatment-related toxicity, and dismal prognosis. We evaluated inotuzumab ozogamicin and dexamethasone (Dex) as induction therapy in older patients with ALL within the German Multicenter Study Group for Adult ALL (GMALL).

Patients And Methods: The open-label, multicenter, phase II, INITIAL-1 trial enrolled 45 patients older than 55 years with newly diagnosed, CD22-positive, -negative B-precursor ALL (B-ALL).

View Article and Find Full Text PDF

Genetic lesions of IKZF1 are frequent events and well-established markers of adverse risk in acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on patient outcome in acute myeloid leukemia (AML) remains elusive. In a multicenter cohort of 1606 newly diagnosed and intensively treated adult AML patients, we found IKZF1 alterations in 45 cases with a mutational hotspot at N159S.

View Article and Find Full Text PDF

Purpose: The goal of this study was to obtain maximum allowed shift deviations from planning position in six degrees of freedom (DOF), that can serve as threshold values in surface guided radiation therapy (SGRT) of breast cancer patients.

Methods: The robustness of conformal treatment plans of 50 breast cancer patients against 6DOF shifts was investigated. For that, new dose distributions were calculated on shifted computed tomography scans and evaluated with respect to target volume and spinal cord dose.

View Article and Find Full Text PDF

Steady states of dynamical systems, whether stable or unstable, are critical for understanding future evolution. Robust steady states, ones that persist under small changes in the model parameters, are desired when modelling ecological systems, where it is common for accurate and detailed information on functional form and parameters to be unavailable. Previous work by Jahedi et al.

View Article and Find Full Text PDF

Purpose: Chemotherapy is pivotal in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC). Technical advances unveiled a high degree of inter- and intratumoral heterogeneity. We hypothesized that intratumoral heterogeneity (ITH) impacts response to gemcitabine treatment and demands specific targeting of resistant subclones.

View Article and Find Full Text PDF
Article Synopsis
  • Approximately 50% of older patients with acute myeloid leukemia (AML) do not achieve complete remission after traditional chemotherapy, and alternatives like higher doses of cytarabine combined with mitoxantrone have low success rates, especially for those with the unfavorable FLT3-ITD marker.* -
  • This study investigates the efficacy of quizartinib, a selective FLT3 inhibitor, combined with a chemotherapy regimen (HAM) in a randomized phase II trial, assessing outcomes such as complete remission rate compared to historical controls.* -
  • The trial employs a novel matched threshold crossing approach to bolster the reliability of results by comparing the current treatment outcomes with data from previous similar studies, aiming to improve the understanding of
View Article and Find Full Text PDF